Kimberly Million
Family · Fort Wayne, INNPI 1871154401
Payments from drug & device makers
Across 331 payments — averaging $14.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- AstraZeneca$447
- Novo Nordisk$358
- Lilly USA, LLC$288
- Sanofi-aventis U.S. LLC$260
- Corium, LLC$194
- plus $2K from 33 others
What the payments were for
- Food & beverage$4,729100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 130 | $1,243 |
| AstraZeneca | 21 | $447 |
| Novo Nordisk | 22 | $358 |
| Lilly USA, LLC | 19 | $288 |
| Sanofi-aventis U.S. LLC | 14 | $260 |
| Corium, LLC | 11 | $194 |
| Pfizer | 9 | $143 |
| Boehringer Ingelheim | 9 | $143 |
| Merck | 9 | $138 |
| Axsome Therapeutics, Inc. | 6 | $125 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $121 |
| Sumitomo Pharma America, Inc. | 5 | $98 |
| Astellas Pharma US Inc | 4 | $87 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $77 |
| GSK | 5 | $76 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $71 |
| Amgen | 5 | $69 |
| Dexcom, Inc. | 4 | $67 |
| Johnson & Johnson | 4 | $66 |
| Eisai Inc. | 3 | $65 |
| Biohaven Pharmaceuticals, Inc. | 4 | $62 |
| Bayer | 3 | $56 |
| Shield Therapeutics Inc | 2 | $54 |
| Antares Pharma, Inc. | 3 | $49 |
| Exact Sciences | 3 | $45 |
| Lundbeck LLC | 2 | $36 |
| Tris Pharma Inc | 2 | $34 |
| Novartis | 2 | $31 |
| Idorsia Pharmaceuticals US Inc | 2 | $31 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| UCB, Inc. | 1 | $28 |
| Abiomed | 1 | $22 |
| Kowa Pharmaceuticals America, Inc. | 1 | $21 |
| Radius Health, Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $17 |
| Tolmar, Inc. | 1 | $13 |
| Amarin Pharma, Inc. | 1 | $13 |
| Acadia Pharmaceuticals Inc | 1 | $12 |
How this compares
$4,729 in reported general payments places this provider in the 90th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 66 | $61,852 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 57 | $52,171 |
| OzempicSemaglutide | 44 | $44,077 |
| MounjaroTirzepatide | 26 | $35,140 |
| JardianceEmpagliflozin | 23 | $30,295 |
| Nurtec OdtRimegepant Sulfate | 14 | $25,687 |
| EliquisApixaban | 19 | $19,289 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 17 | $15,548 |
| XareltoRivaroxaban | 12 | $7,067 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 15 | $6,802 |
| BelsomraSuvorexant | 13 | $5,618 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 22 | $2,346 |
| Celecoxib | 19 | $2,194 |
| Levothyroxine Sodium | 167 | $1,410 |
| Atorvastatin Calcium | 214 | $1,307 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $447 | $61,85266 claims |
| GSKTrelegy Ellipta | $76 | $52,17157 claims |
| PfizerNurtec Odt, Eliquis | $143 | $44,97633 claims |
| Novo NordiskOzempic | $358 | $44,07744 claims |
| Lilly USA, LLCMounjaro | $288 | $35,14026 claims |
| Boehringer IngelheimJardiance | $143 | $30,29523 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $260 | $15,54817 claims |
| Johnson & JohnsonXarelto | $66 | $7,06712 claims |
| MerckBelsomra | $138 | $5,61813 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,392 family providers in Indiana.
Other family in Fort Wayne
- Justin BrownFort Wayne$142K
- Tracy JohnsonFort Wayne$68K
- Grant BlauveltFort Wayne$28K
- Benjamin GiarmoFort Wayne$21K
- Katarzyna SedlaczekFort Wayne$20K
- Brandy DantzerFort Wayne$18K
- Catherine RobertsFort Wayne$13K
- Adam ZuberFort Wayne$13K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.